Message from Serge Weinberg, Chairman of the Board of Directors
I would like to thank you for your participation in our Annual General Meeting that adopted all resolutions. I’m pleased to welcome Emmanuel Babeau as a new Director. His important financial skills and international mindset will be a strong addition to the Board.
The beginning of 2018 was very busy, in particular in terms of acquisitions…
Interview with Olivier Brandicourt, CEO
What are the key highlights of the first quarter of 2018?
In the first quarter, the performance of our global operations, coupled with disciplined expense management, allowed us to manage the impact of the losses of exclusivity for Lantus® and Renvela®/ Renagel® in the United States.
When is the return to growth you announced for 2018 expected?
Return to growth is expected in the second half of 2018. The impact of exclusivity losses should be offset…
Could you tell us more about your new activity in Hematology and Rare Blood Disorders?
In early March we finalized the acquisition of Bioverativ which brings a growing product portfolio: Eloctate® and Alprolix® are part of the standard of care in hemophilia …
First Quarter 2018 Results
Strong Specialty Care and Emerging Markets sales offset exclusivity losses and Vaccines slowdown
In the first quarter of 2018, Company sales were €7,898M, down 8.7% on a reported basis. Exchange rate movements had a negative effect of 8.3 percentage points. At CER, Company sales decreased slightly by 0.4%. At CER/CS, sales were down 1.1%.
A key step to strenghtening innovation in R&D
On May 14, 2018, Sanofi and Ablynx announced the successful results of the initial tender offers to acquire Ablynx shares. Owning more than 95% of Ablynx shares, Sanofi launched a squeeze-out tender on the remaining shares on May 22.
Both companies agreed in January 2018 that Sanofi would acquire Ablynx for around €3.9bn…
Sustaining innovation in R&D
- Dupixent® reviewed as potential treatment for moderate-to-severe asthma
- Dupixent® shows positive Phase 3 results for treatment of atopic dermatitis in adolescents
- Cemiplimab reviewed as a potential treatment for advanced cutaneous squamous cell carcinoma
- Sotagliflozin under review as potential treatment for Type 1 Diabetes
- Sanofi head of global R&D Elias Zerhouni to retire
- Sanofi to invest €350 million in Canadian vaccine facility
- Expected divestiture of Sanofi’s European Generics business
Annual General Meeting 2018
Approval of a dividend of €3.03 per share
The Combined General Shareholders’ Meeting of Sanofi was held on May 2, 2018 in Paris. All resolutions submitted to the vote were adopted by its shareholders, among which the individual company and consolidated financial statements, the distribution of a cash dividend and the renewal of the Board of Directors.
The new edition of the Shareholder Handbook presents key figures for 2017 and the Group’s strategy. It provides information about Sanofi shares and how to manage them as well as practical information for shareholders. U.S. shareholders may also find details on the American Depositary Shares program. In addition, the handbook provides useful contact information and key shareholder events in 2018.